Conference Day Two

10.00 - 17.00 EST | 7.00 - 14.00 PST

* Please note that the following agenda timings are Eastern Standard Time.  

For Pacific Standard Times, please download the full event guide here

10:00 am Chair’s Opening Remarks

Targeting with Anti-TGF-ß Traps

10:15 am Bintrafusp alfa, A Bifunctional Fusion Protein Simultaneously Blocking PD-L1 and TGF-ß in Tumor Microenvironment

  • Adam Lazorchak Group Leader, Oncology & Immunopharmacology, EMD Serono


• Overview of Bintrafusp Alfa as an anti-PD-L1 antibody linked to TGF-ß trap, why was this approach taken
• Preclinical data demonstrating antitumor efficacy, pharmacodynamic effects and immunological responses
• Potential combination partner with standard of care therapy in preclinical model

10:45 am Bintrafusp alfa: It Takes Two To Tango

  • James Gulley Chief, Genitourinary Malignancies Branch Head, Immunotherapy Group, GMB Director, Medical Oncology Service, Center for Cancer Research, NCI, NIH


• Brief rationale for targeting TGF-ß and overview of phase 1
• Clinical Data in Lung Cancer
• Clinical Data in HPV associated malignancies

11:15 am Speed Networking – Get Matched With Your Peers on the Platform for 1-2-1 Introductions

11:45 am Short Presentation From Poster Session Winner – Discover the Next up and Coming TGF-ß Pioneer!

Advancing Antibody Approaches

12:00 pm The Anti-TGFβ Neutralizing Antibody, SAR439459, Blocks the Immunosuppressive Effects of TGFβ & Inhibits the Growth of Syngeneic Tumors in Combination with anti-PD1

  • Sharad Sharma Senior Principal Scientist & Lab Head, Oncology Research, Sanofi

12:30 pm Inhibition of TGFβ1 Activation with SRK-181 to Overcome Primary Resistance to Checkpoint Inhibition Therapy


• Retrospective analyses of clinical tumor samples have identified the TGFβ pathway as a potential contributor to primary resistance to checkpoint inhibition therapy
• Selective inhibition of TGFβ1 activation with SRK-181 induces profound combination treatment effects with anti–PD-1 on tumor growth in checkpoint inhibition therapy-resistant tumors
• TGFβ1 isoform specificity of SRK-181 results in improved preclinical toxicity profile in comparison to less selective TGFβ inhibition

1:00 pm TGFβ-Blockade Uncovers Stromal Plasticity in Tumors by Revealing the Existence of a Novel Subset of Interferon- Licensed Fibr


• Studies in preclinical mouse models demonstrated that TGFβ-neutralization leads to a profound remodeling of CAF dynamics
• Changes in the CAF landscape correlated with productive anti-tumor immunity
• These findings lay the foundation for future investigations aimed at defining combinatorial drug partners for TGFβ-antagonists in the clinic

2:00 pm Networking Lunch

Dissecting the Dual Relationships between CAR-T & TGF-ß

2:30 pm Inhibition of TGF-ß Signaling in Gene-Edited Allogenic CAR-T Cells

  • Aaron Martin Senior Scientist, Cell Therapy Discovery, Precision BioSciences


• Precision BioSciences uses ARCUS gene editing to precisely insert a CAR transgene at a specific TCR knockout site in healthy donor T cells, enabling the manufacture of off-the-shelf allogeneic CAR T products with a single editing step
• One component of the CAR transgene is a potent, stable, and well tolerated RNAi sequence that can be used to target a variety of transcripts that impact T cell activity
• We have used this feature to reduce the abundance of TGFbRII on the surface of CAR T cells, affording the cells superior expansion and target killing capabilities in environments that are normally immunosuppressive

3:00 pm Fireside Chat: TGF-ß’s Role in the Suppressive Function of T Cells in the TME – Challenges & Opportunities

  • Paul Rennert President & Chief Scientific Officer, Aleta Biotherapeutics
  • Aaron Martin Senior Scientist, Cell Therapy Discovery, Precision BioSciences
  • Christopher Heery Chief Medical Officer, Precision BioSciences


Interactive Session – Share your audio, video and join in the discussion with our round table leaders and discuss

  1. What is TGF-ß’s role in the suppressive function of T cell in the TME and potential to combine anti-TGF-ß with CAR-T cell therapy?
  2. Defining a therapeutic window using targeted PK/ PD approach – what are your key challenges?
  3. Technology to advance your pipeline – from next generation models to advanced RNA seq analysis, what do you need to expedite your candidate to clinic?

ATAC Platform & Antisense Agents

3:45 pm Antisense Agents in TGF-ß for Immuno-Oncology Drug Development


• Oncotelic is developing a TGF-β2 antisense agent (OT-101) as an immunotherapy against pancreatic cancer, melanoma, and glioblastoma
• Why TGF-β2? Safety, toxicity and efficacy data available from studies so far
• Use of OT-101 in combination with other standard cancer therapies to establish an effective multi-modality treatment strategy for difficult-to treat cancers
• Use of OT-101 against COVID-19 and other viral infections

4:15 pm Development of Immune Cell Targeted TGF-ß Therapies to Restore Tumor Clearance in Cancer Patients


• In cancer patients, TGF-ß mediated immune suppression blocks tumor clearance
• Blockade of TGF-ß signaling in immune cells is necessary and sufficient to rescue tumor clearance
• At Synthis, we are developing first in class therapeutic platform to selectively and safely block TGF-ß mediated immune suppression

4:45 pm Chair’s Closing Remarks